

# TRANSITIONS

A NEWSLETTER FOR EQUITY HOLDERS OF TRT

## CWI Goes International

TRT's Combat Wound Initiative (CWI) has gone international. In September, Hadassah Hebrew University Medical Center Mount Scopus in Jerusalem, Israel became the fifth site to participate in the CWI study. CWI is TRT's FDA trial on the use of the DermaGold™ for treatment of acute soft tissue wounds.

Under the direction of primary investigator, Dr. Aviram Nissan, and investigator in charge, Dr. Ofer Elishoov, the study at Hadassah is expected to begin enrolling patients mid-October and to continue until the completion of the CWI.

The physicians at Hadassah were trained by Dr. Wolfgang Schaden, TRT's Director of Scientific Research, during his recent visit to Jerusalem. The Hadassah lab technicians travelled to Walter Reed Army Medical Center, initial study site of the CWI, to receive training in late September.

This expansion not only takes the CWI to an international level but also helps expedite completion of the CWI by increasing patient enrollment. By the end of this year we expect to have treated approximately **40%** of the patients to be included in this study. We look forward to providing a year-end update in the next newsletter!

## CRT Update

TRT's cardiac subsidiary, Cardiac Regeneration Technologies, is pleased to announce the remarkable results of the eleven open heart patients who were treated with our patented CardioGold technology. All patients are doing very well having reported significant improvement of their overall condition and unprecedented EF (ejection fraction) increases averaging 15-25%. One patient showed EF improvement of more than 40% at 6-month follow-up!

Such favorable patient reaction to the treatment and noticeable improvement in their quality of life is highly encouraging.

Per our business plan, CRT is presenting its experimental, animal and clinical results to potential strategic partners and will commence phase II studies upon successfully consummating a partnership.

## More Patents!

TRT received 3 more Notices of Allowance from the United States Patent and Trademark Office (USPTO) this quarter. This brings to twelve the total number of our key unfocused technology patents awarded to date!

The most recent patent awards using TRT's proprietary unfocused technology include claims to:

- 1) treat reproductive organs in patients diagnosed with infertility or impotence;
- 2) activate cells within treated tissue thereby releasing growth factor proteins or other chemical compositions promoting growth and accelerating germination or plant growth; and
- 3) attach or reattach a ligament, tendon, cartilage or other soft tissue to a bone mass.

Several additional applications are pending and we anticipate award dates in the fourth quarter.

These patent awards continue to strengthen TRT's position as the premier shockwave company and inventor of unfocused shockwaves. We look forward to bringing you news of more patent awards in the near future.

## Another \$1.2 Mio in DAC Funding

The Combat Wound Initiative (CWI) was awarded an additional \$1.2M from the Defense Acquisition Challenge (DAC) program to accelerate the projected completion date of the program by adding additional sites.

The purpose of the DAC initiative is to identify and accelerate the development and approval of technologies that can have the greatest positive financial impact for the Department of Defense (DOD) in the future and aid our soldiers. DAC selected TRT technology, from among hundreds of companies that submitted applications, as having the greatest potential to save the DOD future financial resources and improve the quality of care for our nation's soldiers.



# Around the World

## European Academy of Wound Technology



The European Academy of Wound Technology (“EAWT”) held its 4<sup>th</sup> annual conference July 6-8 in Paris, France. EAWT was established to promote the latest innovations and advances in wound care treatment especially for hard-to-treat wounds such as diabetic skin ulcers. The annual conferences provide a platform for physicians, nurses, clinicians and academics to discuss and learn the newest treatment techniques.

The meeting was led by President Dr. Luc Téot, one of the world’s most renowned wound care specialists and included participants from all over the world. Attendees were trained to apply the newest technologies, including DermaGold™ MultiWave™ technology, to difficult chronic wounds. Dr. Hanna Kaufmann, President of the Israeli Wound Care Society, demonstrated the use of the DermaGold, which is already an integrated technology for wound care in Israel.

All conference participants had the opportunity to learn how to operate the DermaGold. Dr. Téot was so impressed by its ease of use and effectiveness that he will begin a DermaGold trial in his wound care clinic in Montpellier, France in October.

## Mediterranean Games 2009

TRT’s Italian distributor, HMT Srl, took part in the Mediterranean Games held in Pescara, Italy this summer. Supported by HMT Srl, Professor Raoul Saggini of the University of Chieti, Italy held a lecture on the OrthoGold100™ entitled "*Innovative Methods with Advanced Physical Energies in the Rehabilitation of High-level Athletes*" during the games’ techno-scientific workshop. This workshop was attended by physicians and trainers for some of the world’s top athletes gaining TRT purchase in the international sports medicine arena.



The Mediterranean Games, primarily for countries bordering the Mediterranean Sea, are a small version of the Olympic Games and therefore are overseen by the International Olympic Committee. The games have been held every four years since 1951 and are now held the year following the summer Olympics.

## Device Sales Strong

TRT’s European subsidiary, MTS Europe GmbH, is successfully driving sales of our OrthoGold100 and has delivered 25 devices to date! Customer feedback is highly positive and we expect strong ROW (rest of world) sales through the end of the year.

# Across the Nation

## LithoGold™ at World Congress

Dr. James Lingeman, one of the world's foremost experts on shock-wave lithotripsy, recently presented TRT’s LithoGold™ lithotripsy system at the World Congress of Endourology and Shockwave Lithotripsy in Munich, Germany. The five-day congress brought together approximately 2,000 of the world’s top urologic surgeons to discuss the latest therapeutic techniques and medical treatments through information sessions, educational courses, hands-on courses, and live surgeries.



Dr. Lingeman presented his findings from a prospective evaluation performed from November 2008 to April 2009 on 155 patients treated with TRT’s LithoGold™.

Tissue Regeneration Technologies, LLC	
110 Arnold Mill Park, Suite 400, Woodstock, GA 30188	
Tel: (770) 966-1315	
TDD: (877) 966-1315	
Fax: (770) 592-8910	
Web: www.trtllc.com	

